Systemic Inflammation Response Index and weight loss as prognostic factors in metastatic pancreatic cancer: A concept study from the PANTHEIA-SEOM trial

Table 1 Patient demographics

		N = 50
Sex	Male	32 (64%)
	Female	18 (36%)
Age	mean ± SD	63.74 ± 11.2
	Median (p25-p75)	66.7 (58-71)
	Range	32-85
ECOG-PS	0	16 (32%)
	1	25 (50%)
	2	9 (18%)
Comorbidities: Charlson Index	No	39 (78%)
	Yes	11 (22%)
Weight loss > 5% of body weight1	No	23 (46%)
	Yes	21 (42%)
	N/A	6 (12%)
1st line palliative chemotherapy	mFOLFIRINOX	14 (28%)
	Gemcitabine + Nab/Paclitaxel	25 (50%)
	Gemcitabine	8 (16%)
	Capecitabine	3 (6%)
Stage	4	50 (100%)
Site of distant metastases	Only liver	18 (36%)
	Only peritoneal carcinomatosis	6 (12%)
	Only lung	5 (10%)
	> 1 location	21 (42%)

¹Weight loss > 5% in the 3 mo prior to diagnosis.

ECOG-PS: Eastern Cooperative Group Performance Status; N/A: Not applicable; mFOLFIRINOX: Modified fluorouracil, leucovorin, irinotecan and oxaliplatin.

Table 2 Univariate analysis of patients’ characteristics and their association with overall survival and progression free survival

Variable	OS				PFS
	Sig	HR	Lower	Upper	Sig	HR	Lower	Upper
Female	0.373	1.34	0.701	2.573	0.236	1.457	0.782	2.713
Age	0.392	0.97	0.934	1.027	0.857	0.99	0.951	1.042
Comorbidities	0.795	1.10	0.536	2.259	0.106	1.80	0.882	3.687
ECOG PS	0.194	1.32	0.865	2.036	0.079	1.51	0.953	2.418
Weight loss > 5%1	0.007	2.77	1.316	5.848	0.120	1.68	0.874	3.234
Albumin levels	0.366	1.40	0.674	2.915	0.08	1.84	0.918	3.705
Site of metastases	0.542	1.07	0.851	1.359	0.84	0.97	0.779	1.228
CA 19-9 ≥ 37 U/mL	0.776	1.13	0.465	2.788	0.531	1.30	0.570	2.974
CA 19-9 ≥ 1000 U/mL	0.258	1.49	0.744	3.016	0.215	1.51	0.786	2.910
Chemotherapy	0.264	1.16	0.892	1.519	0.017	1.432	1.065	1.924
SIRI ≥ 2.3 × 103	0.000	5.02	2.375	10.614	0.000	4.04	1.989	8.238

¹Weight loss > 5% in the 3 mo prior to diagnosis.

Sig: Significance; HR: Hazard ratio; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; SIRI: Systemic Inflammation Response Index; OS: Overall survival; PFS: Progression free survival; CA 19-9: Carbohydrate antigen 19-9.

Table 3 Multivariate analysis of patient characteristics and their association with overall survival and progression free survival

Variable	OS				PFS
	Sig	HR	Lower	Upper	Sig	HR	Lower	Upper
Weight loss > 5%1	0.158	1.94	0.772	4.901	0.838	1.08	0.481	2.465
ECOG PS	0.512	0.754	0.325	1.753	0.043	0.381	0.150	0.968
SIRI ≥ 2.3 × 109	0.001	4.97	1.882	13.138	0.000	8.75	2.771	27.668
Chemotherapy	0.118	1.55	0.894	2.714	0.001	2.867	1.524	5.396

¹Weight loss > 5% in the 3 mo prior to diagnosis.

Sig: Significance; HR: Hazard ratio; SIRI: Systemic Inflammation Response Index; OS: Overall survival; PFS: Progression free survival; ECOG PS: Eastern Cooperative Group Performance Status.

Table 4 χ² test examining the association between weight loss and systemic inflammation response index

		SIRI ≥ 2.3
		No	Yes	Total
Weight loss > 5%1	No	20	6	26
	Yes	3	21	18
Total		23	21	44

¹Weight loss > 5% in the 3 mo prior to diagnosis.

Pearson χ²: Value = 15480, asymptotic significance = 0.000. SIRI: Systemic Inflammation Response Index.

Table 5 χ² test examining the association between albumin levels and systemic inflammation response index

		SIRI ≥ 2.3
		No	Yes	Total
Albumin < 3.5 g/dL1	No	9	3	12
	Yes	18	15	33
Total		27	18	45

¹Plasmatic albumin levels at diagnosis.

Pearson χ²: Value = 1534, asymptotic significance = 0.215. SIRI: Systemic Inflammation Response Index.